Ilya Pharma approved for funding by the European Innovation Council Equity Fund for high-impact innovation
Bloomberg reports: EU will become shareholder in startups for the first time.
News
Ilya Pharma announces positive results from Phase I trial of lead candidate ILP100 and rapid move to Phase II
Success also de-risks the use of ILP-drug candidates in other medical indications, including the company’s inflammatory bowel disease program.
Latest clinical developments and next raise to be presented at EIC Investor Day 2.0 17-18 December
FDA open to new endpoints for patients with difficult wounds
FDA opened for 5 new endpoints in Nov 2020 (vs. only 1 until then) following thorough work by FDA’s Inter-center Wound Healing Work group and industry Wound Experts/FDA Clinical Endpoints Project.
Meet Ingemar Kihlstörm - facilitating the next stage of growth
Financing innovations in pharmaceutical development – facilitating the next stage of growth
Operational Report Q3 2020